Filing Details

Accession Number:
0001415889-24-021452
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-08-16 16:09:38
Reporting Period:
2024-08-14
Accepted Time:
2024-08-16 16:09:38
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1370053 Anaptysbio Inc ANAB Pharmaceutical Preparations (2834) 203828755
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1711462 F. Paul Lizzul C/O Anaptysbio, Inc.
10770 Wateridge Circle, Suite 210
San Diego CA 92121
Chief Medical Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-08-14 2,000 $18.50 13,618 No 4 M Direct
Common Stock Disposition 2024-08-14 2,000 $40.00 11,618 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Common Disposition 2024-08-14 2,000 $0.00 2,000 $18.50
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
86,500 2030-07-29 No 4 M Direct
Footnotes
  1. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2023.
  2. The stock option vests and becomes exercisable as to 25% of the shares subject to the option on July 31, 2021, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
  3. In addition to the remaining options to purchase 86,500 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 297,610 shares of common stock, which options vest according to their terms.